Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

SANUWAVE Health (SNWV) EBITDA Margin (2016 - 2026)

SANUWAVE Health has reported EBITDA Margin over the past 17 years, most recently at 14.96% for Q1 2026.

  • Quarterly EBITDA Margin rose 5059.0% to 14.96% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 37.2% through Mar 2026, up 13226.0% year-over-year, with the annual reading at 26.82% for FY2025, 12782.0% up from the prior year.
  • EBITDA Margin was 14.96% for Q1 2026 at SANUWAVE Health, down from 57.43% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 260.18% in Q4 2023 and troughed at 478.36% in Q3 2023.
  • The 5-year median for EBITDA Margin is 65.55% (2025), against an average of 75.51%.
  • Year-over-year, EBITDA Margin surged 36966bps in 2022 and then crashed -45102bps in 2023.
  • A 5-year view of EBITDA Margin shows it stood at 109.47% in 2022, then skyrocketed by 338bps to 260.18% in 2023, then plummeted by -150bps to 128.86% in 2024, then soared by 145bps to 57.43% in 2025, then crashed by -126bps to 14.96% in 2026.
  • Per Business Quant, the three most recent readings for SNWV's EBITDA Margin are 14.96% (Q1 2026), 57.43% (Q4 2025), and 85.96% (Q3 2025).